National Institute Of Allergy And Infectious Diseases (niaid)
Clinical trials sponsored by National Institute Of Allergy And Infectious Diseases (niaid), explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Bird flu rechallenge: scientists Re-Infect volunteers to unlock immune secrets Results expected Sep 2026 (estimated)
- Could a stem cell transplant tame Hard-to-Control MS? Results expected Oct 2026 (estimated)
- New west nile vaccine enters first human tests Results expected Oct 2026 (estimated)
- Healthy volunteers willingly catch the flu for science Results expected Oct 2026 (estimated)
- Could a cancer drug tame rare clotting disorder? Results expected Oct 2026 (estimated)
-
Experimental HIV vaccine trial ends early – what we know
Vaccine Stopped earlyThis early-stage trial tested an experimental HIV vaccine in 44 healthy adults to see if it was safe and triggered an immune response. The vaccine uses a piece of the HIV virus (fusion peptide) to train the body's defenses. The study was terminated early, so the full results are …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
Ebola vaccine in a nasal spray? early trial halted
Vaccine Stopped earlyThis early-stage trial tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus. The study aimed to check safety and immune response, but it was terminated early, so results are limited.
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 11:03 UTC
-
Could a new drug help preserve insulin production in type 1 diabetes?
Disease control Stopped earlyThis early-stage trial tested four different doses of siplizumab in 8 people aged 8–45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that changes certain immune cell patterns linked to better insulin production. Participants r…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Rheumatoid arthritis combo drug trial stalls after just 2 patients
Disease control Stopped earlyThis early-stage trial tested whether adding an experimental drug called VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis. Only 2 participants were enrolled before the study was terminated, so no meaningful conclusions ca…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a 3-Month TB cocktail replace the standard 6-Month regimen?
Disease control Stopped earlyThis clinical trial investigates whether a 3-month combination of clofazimine and rifapentine can effectively treat drug-susceptible tuberculosis (TB) compared to the standard 6-month regimen. The study includes adults with pulmonary TB, some of whom also have HIV. Researchers ar…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Mpox drug trial halted: did tecovirimat help?
Disease control Stopped earlyThis study tested whether the drug tecovirimat could safely treat mpox and speed up recovery. About 719 people with mpox took either tecovirimat or a placebo. The main goals were to see if the drug reduced the time for skin lesions to heal and lessened pain. The study was termina…
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Hormone therapy and HIV drugs: a delicate balance for transgender women
Disease control Stopped earlyThis study looked at how feminizing hormone therapy (estradiol) interacts with HIV medications in transgender women living with HIV. It included 93 participants who were already on HIV treatment and gave them standardized estradiol doses for up to 48 weeks. The goal was to see if…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug for rare inflammatory disease shows early promise but trial cut short
Disease control Stopped earlyThis study tested elotuzumab, a drug used for multiple myeloma, in people with active IgG4-related disease (IgG4-RD), a rare condition causing inflammation and organ damage. The trial was small (only 8 participants) and was terminated early, so it is unclear if the drug is safe o…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lupus drug combo tested in tiny trial – but study halted early
Disease control Stopped earlyThis phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 15:22 UTC
-
Could a tiny ear device ease arthritis pain in kids?
Symptom relief Stopped earlyThis study tested whether a small device that sends mild electrical pulses to the vagus nerve (through the ear) can reduce pain and inflammation in children with juvenile idiopathic arthritis. The trial planned to enroll children ages 5 to 18, but was terminated early after only …
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Can your first flu shape how well the vaccine works?
Knowledge-focused Stopped earlyResearchers are studying how a person's age, first flu exposure, and vaccination history affect the immune system's response to the seasonal flu shot. Healthy adults and children aged 9 and older receive a standard quadrivalent flu vaccine, with blood samples taken before and aft…
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Pregnancy drug study aims to protect moms and babies from HIV and TB
Knowledge-focused Stopped earlyThis study looked at how HIV and tuberculosis (TB) medications are processed in the bodies of pregnant women and new mothers. Researchers measured drug levels in the blood of 205 women during pregnancy and after delivery to see if standard doses are effective. The goal was to gat…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC